Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
Recommendation

Tuesday, 10 November 2026 9 .00 - 17.00 h
In Pharmeuropa, the “Comments concerning texts published in Issue 12.3” have been published. This provides the explanations relating to the new, revised and corrected texts adopted by the European Pharmacopoeia Commission. These include two chapters on dissolution testing:
- 2.9.42. Dissolution test for lipophilic solid dosage forms
- 2.9.43. Apparent dissolution
Both texts were previously published for comment in Pharmeuropa Issue 36.3. Further information on the changes can also be found in the PDF document published in Pharmeuropa.
The new texts will be published in Edition 12.3 of the European Pharmacopoeia in January 2026 and will be effective from 1 July 2026.
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus


